Wayne Gombotz - Alpine Immune Chief Officer
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Executive
Dr. Wayne R. Gombotz Ph.D. is Chief Technology Officer of the company. Dr. Gombotz has more than 30 years experience in the biotech and pharma industries and most recently served as the Chief Development Officer at Immune Design. As Chief Development Officer at Immune Design, Dr. Gombotz was responsible for advancing several immunooncology products from bench to pivotal clinical trials. Prior to Immune Design, He held senior roles at Omeros Corporationrationration, Corixa Corporationrationration, and Amgen, where he played a major role in the development and launch of ENBREL, one of the topselling drugs for psoriasis and multiple arthritis conditions. Dr. Gombotz currently serves as an Advisory Board Member for the University of Washington Department of Bioengineering and was a recent recipient of the University of Washington College of Engineering 2019 Diamond Award for Distinguished Achievement in Industry since 2019.
| Age | 65 |
| Tenure | 5 years |
| Phone | 206 788 4545 |
| Web | https://www.alpineimmunesciences.com |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emil MD | Terns Pharmaceuticals | 44 | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| David CFA | Bicycle Therapeutics | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Elizabeth JD | IGM Biosciences | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Alethia Young | Bicycle Therapeutics | 45 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Temre Johnson, Head Communications | ||
| Remy Durand, Chief Officer | ||
| Andrew MD, Chief Officer | ||
| Paul Rickey, CFO, Senior Vice President Secretary | ||
| Stanford MD, President Development | ||
| Wayne Gombotz, Chief Officer | ||
| Mitchell MD, Executive CEO | ||
| Pamela Holland, VP Research | ||
| Wolfgang MD, Chief Officer | ||
| Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |